Hansoh Pharmaceutical Group Introduces Breakthrough B7-H3-Targeted Antibody-Drug Conjugate (ADC) HS-20093
Hansoh Pharmaceutical Group has announced that its B7-H3-targeted antibody-drug conjugate (ADC), HS-20093, has received approval for breakthrough therapy designation from the National Medical Products Administration (NMPA) of China.
The proposed indication for HS-20093 is extensive-stage small cell lung cancer (ES-SCLC) that develops following standard first-line treatment, which typically includes platinum doublet chemotherapy combined with immunotherapy.
HS-20093 is a novel ADC that features a fully humanized anti-B7-H3 monoclonal antibody linked to a topoisomerase inhibitor (TOPOi) payload. It is currently being evaluated in clinical studies in China, including a phase III trial for small cell lung cancer, as well as multiple phase I and II studies for sarcoma, head and neck cancers, esophageal squamous cell carcinoma (ESCC), and other solid tumors.
Lung cancer is among the most prevalent cancers globally. In patients with small cell lung cancer, approximately 70 percent present with extensive-stage disease, indicating that the cancer has metastasized throughout one or both lungs and/or to other areas of the body. ES-SCLC is an aggressive form of cancer that is challenging to treat and offers limited therapeutic options.
The five-year survival rate for ES-SCLC is around 3 percent. Most patients experience a relapse following initial treatment, with the median overall survival for those with relapsed ES-SCLC being only 5 to 6 months with current standard-of-care treatments.
